US Stock MarketDetailed Quotes

OPRX OptimizeRx

Watchlist

10.700
+0.280+2.69%

Close May 2 16:00 ET

10.700
0.0000.00%

Post 16:00 ET

194.57MMarket Cap-10388P/E (TTM)

OptimizeRx Stock Forum

Moomoo AI

Mar 15 20:14

Recent insider selling at OptimizeRx, especially by Marion Odence-Ford, may worry potential investors. The absence of insider buying and insignificant share ownership by insiders hint at possible doubts about future performance.

OptimizeRx's Stock Sinks To US$12.92, But Insiders Sold Even Lower

Moomoo AI

Dec 21, 2023 20:04

OptimizeRx's high P/S ratio may suggest that investors anticipate a turnaround in the company's revenue performance. This could indicate shareholders' strong future revenue expectations.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 20:01

The high P/S ratio at OptimizeRx suggests investors expect a reversal of the company's downtrend in revenue. Shareholders seem to hold stocks with hope for the company's promising future.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 20:01

Investors at OptimizeRx might be anticipating a reversal in its poor revenue performance, hence the high P/S ratio. Shareholders potentially retain stocks expecting the company's bright future.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 19:54

Investors at OptimizeRx may be expecting a turnaround in the company's poor revenue performance, hence the high P/S ratio. This could reflect shareholders' strong future revenue expectations.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Nov 14, 2023 18:43

Analysts exhibit growing optimism towards OptimizeRx, driven by notable hike in revenue expectations. The current market conditions indicate a potential good time for reassessing OptimizeRx.

News Flash: Analysts Just Made A Huge Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Forecasts

Moomoo Breakfast US

Aug 10, 2022 20:45

ColumnsToday's pre-market stock movers: RBLX, TTD, VLD, WYNN and more

Gainers:
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US)$+17%,$Workiva(WK.US)$ +15.3%,$Arlo Technologies(ARLO.US)$ +12%,$Array Technologies(ARRY.US)$ +10.3%,$Everbridge(EVBG.US)$ +9.7%,$Catalyst Pharmaceuticals(CPRX.US)$ +9.4%,$Halozyme Therapeutics(HALO.US)$ +8.7%,$Velo3D(VLD.US)$ +7.6%,$CyberArk(CYBR.US)$ + 6.2%,$Haemonetics(HAE.US)$ +5.8%,$Jackson Financial(JXN.US)$ +5.7% (also increases dividend),$Axon Enterprise(AXON.US)$ +4.8%,...

Analysts Notebook

Jul 15, 2022 20:38

ColumnsTop upgrades and downgrades on 7/15: QCOM, DAL, CSCO, DRE and more

Upgrades
• $Allogene Therapeutics(ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp(CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
•$TechnipFMC(FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern(NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...

Analysts Notebook

Jul 1, 2022 19:54

ColumnsTop upgrades and downgrades on 7/1: CMCSA, FDX, XPEV, HOG and more

Upgrades
• $Coupang(CPNG.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US)$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...

ConchTrader

Nov 9, 2021 04:16

Started a Position 😉🍺☮️

$OptimizeRx(OPRX.US)$ Been sideways for 7 days , earnings tomorrow, closest it’s been to the 21ma in a while. volume drying up, hoping on an earnings move. great story, digital med records, taking market share. BlackRock leading investor. I’m at 94.40

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall